vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and TRANSCONTINENTAL REALTY INVESTORS INC (TCI). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $12.1M, roughly 1.5× TRANSCONTINENTAL REALTY INVESTORS INC). TRANSCONTINENTAL REALTY INVESTORS INC runs the higher net margin — 68.8% vs 65.7%, a 3.0% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 2.3%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 0.7%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.
SCYX vs TCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $12.1M |
| Net Profit | $12.3M | $8.3M |
| Gross Margin | — | — |
| Operating Margin | 56.3% | -28.9% |
| Net Margin | 65.7% | 68.8% |
| Revenue YoY | 1808.5% | 2.3% |
| Net Profit YoY | 376.5% | 7577.8% |
| EPS (diluted) | $0.25 | $0.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $12.1M | ||
| Q3 25 | $334.0K | $12.8M | ||
| Q2 25 | $1.4M | $12.2M | ||
| Q1 25 | $257.0K | $12.0M | ||
| Q4 24 | $977.0K | $11.8M | ||
| Q3 24 | $660.0K | $11.6M | ||
| Q2 24 | $736.0K | $11.8M | ||
| Q1 24 | $1.4M | $11.9M |
| Q4 25 | $12.3M | $8.3M | ||
| Q3 25 | $-8.6M | $724.0K | ||
| Q2 25 | $-6.9M | $169.0K | ||
| Q1 25 | $-5.4M | $4.6M | ||
| Q4 24 | — | $108.0K | ||
| Q3 24 | $-2.8M | $1.7M | ||
| Q2 24 | $-14.5M | $1.5M | ||
| Q1 24 | $411.0K | $2.5M |
| Q4 25 | 56.3% | -28.9% | ||
| Q3 25 | -2516.5% | -10.9% | ||
| Q2 25 | -701.0% | -6.8% | ||
| Q1 25 | -3350.2% | -5.3% | ||
| Q4 24 | — | -14.3% | ||
| Q3 24 | -1563.6% | -14.4% | ||
| Q2 24 | -1255.0% | -9.2% | ||
| Q1 24 | -692.5% | -11.2% |
| Q4 25 | 65.7% | 68.8% | ||
| Q3 25 | -2572.2% | 5.6% | ||
| Q2 25 | -504.8% | 1.4% | ||
| Q1 25 | -2097.7% | 38.5% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | -425.5% | 14.7% | ||
| Q2 24 | -1964.4% | 12.7% | ||
| Q1 24 | 29.9% | 21.4% |
| Q4 25 | $0.25 | $0.97 | ||
| Q3 25 | $-0.17 | $0.08 | ||
| Q2 25 | $-0.14 | $0.02 | ||
| Q1 25 | $-0.11 | $0.53 | ||
| Q4 24 | — | $0.01 | ||
| Q3 24 | $-0.06 | $0.20 | ||
| Q2 24 | $-0.30 | $0.17 | ||
| Q1 24 | $0.01 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $89.0M |
| Total DebtLower is stronger | — | $210.8M |
| Stockholders' EquityBook value | $49.4M | $846.7M |
| Total Assets | $59.0M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | $89.0M | ||
| Q3 25 | $37.9M | $82.7M | ||
| Q2 25 | $44.8M | $73.5M | ||
| Q1 25 | $40.6M | $88.6M | ||
| Q4 24 | $59.3M | $99.7M | ||
| Q3 24 | $68.8M | $131.6M | ||
| Q2 24 | $73.0M | $127.5M | ||
| Q1 24 | $80.2M | $130.8M |
| Q4 25 | — | $210.8M | ||
| Q3 25 | — | $223.5M | ||
| Q2 25 | — | $212.4M | ||
| Q1 25 | — | $198.2M | ||
| Q4 24 | — | $181.9M | ||
| Q3 24 | — | $180.3M | ||
| Q2 24 | — | $177.4M | ||
| Q1 24 | — | $178.3M |
| Q4 25 | $49.4M | $846.7M | ||
| Q3 25 | $36.4M | $838.4M | ||
| Q2 25 | $44.5M | $837.7M | ||
| Q1 25 | $50.5M | $837.3M | ||
| Q4 24 | $55.1M | $832.3M | ||
| Q3 24 | $58.5M | $832.2M | ||
| Q2 24 | $60.4M | $830.4M | ||
| Q1 24 | $74.1M | $828.9M |
| Q4 25 | $59.0M | $1.1B | ||
| Q3 25 | $51.1M | $1.1B | ||
| Q2 25 | $60.7M | $1.1B | ||
| Q1 25 | $67.9M | $1.1B | ||
| Q4 24 | $90.6M | $1.1B | ||
| Q3 24 | $99.0M | $1.1B | ||
| Q2 24 | $107.8M | $1.0B | ||
| Q1 24 | $118.3M | $1.0B |
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.22× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $-2.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.50× | -0.35× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | $-2.9M | ||
| Q3 25 | $-8.7M | $8.2M | ||
| Q2 25 | $-7.5M | $-2.9M | ||
| Q1 25 | $-7.5M | $-7.4M | ||
| Q4 24 | $-24.0M | $1.3M | ||
| Q3 24 | $765.0K | $13.7M | ||
| Q2 24 | $-10.9M | $-511.0K | ||
| Q1 24 | $-4.0M | $3.9M |
| Q4 25 | 1.50× | -0.35× | ||
| Q3 25 | — | 11.28× | ||
| Q2 25 | — | -17.24× | ||
| Q1 25 | — | -1.61× | ||
| Q4 24 | — | 12.13× | ||
| Q3 24 | — | 8.03× | ||
| Q2 24 | — | -0.34× | ||
| Q1 24 | -9.75× | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
TCI
Segment breakdown not available.
